ArticleACS omega2026
Dental Follicle-Derived Mesenchymal Stem Cell Exosome-Loaded Three-Dimensional Electrospun Poly(ε-caprolactone)/Gelatin Scaffold Accelerates Diabetic Foot Wound Healing.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers are chronic wounds characterized by persistent inflammation and insufficient angiogenesis, leading to delayed healing and substantial clinical burden. This study presents a combined platform in which dental follicle-derived mesenchymal stem cell exosomes (DF-MSC-Exos) are integrated into three-dimensional (3D) electrospun poly-(ε-caprolactone)/gelatin (PCL/GEL) nanofiber scaffolds. The 3D scaffoldsfabricated using a custom collectorexhibited high porosity, rapid wettability, and water-vapor permeability conducive to cell infiltration and a moist wound environment. DF-MSC-Exos (200 μg per 2 × 5 mm scaffold) were loaded onto the nanofibers and evaluated in a streptozotocin-induced diabetic rat foot wound model. Compared with controls and blank scaffolds, exosome-loaded scaffolds accelerated wound closure (reaching 92.5 ± 2.4% by day 21 compared to 61.4 ± 4.0% for control), improved tissue organization, and reduced inflammatory infiltration by H&E analysis. Immunohistochemistry revealed a significant decrease in fibroblast growth factor in the NF + Exos group, a pattern consistent with enhanced early re-epithelialization and tempered late-phase fibroplasia; VEGF exhibited a modest pro-angiogenic increase. These histological and molecular readouts align with a pro-regenerative trajectorylower leukocytic burden, earlier epithelial coverage, and remodeling compatible with improved scar quality. In summary, DF-MSC-Exos delivered from a 3D PCL/GEL scaffold provide complementary structural guidance and sustained paracrine signaling, yielding faster and qualitatively superior healing in chronic diabetic wounds. This nanofiber-exosome platform is clinically relevant and scalable, and merits further mechanistic and translational evaluation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.